One of these four patients suffered from PD at 14.47 months (62 weeks); another female patient with leiomyosarcoma achieved long-term SD for 24 months, but then switched to anti-PD-L1 therapy; one patient with a PR of metastatic undifferentiated pleomorphic sarcoma quit the trial at 16.1 months (69 weeks; Fig. 3A, B); and one patient with metastatic synovial sarcoma in her lung achieved SD for 22.3 months, but developed grade II HFS, grade II proteinuria, and grade I HTN (Fig. 3c–f). This evidence concerns the gene CD274 and hypertensive disorder.